Trials / Recruiting
RecruitingNCT05918445
PM8002 in the Treatment of Patients With Advanced Solid Tumors
Phase Ib/IIa Safety and Efficacy of PM8002, a Bispecific Antibody Targeting PD-L1 and VEGF-A, as a Monotherapy in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 380 (estimated)
- Sponsor
- Biotheus Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PM8002 | IV infusion |
Timeline
- Start date
- 2021-03-09
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
- First posted
- 2023-06-26
- Last updated
- 2024-12-05
Locations
48 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05918445. Inclusion in this directory is not an endorsement.